News Sentiment

VNDA sentiment intelligence

Vanda Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.24 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+0.5% over one week, +6.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Vanda Reports Positive Opinion for Imsidolimab Orphan Drug Label

Market Reaction

Balanced read

53/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.5% Price digesting
Trend fit Trend inactive 6.3% over four weeks
Fair value 20.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 34
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 8
Stock Titan 7
simplywall.st 5
PR Newswire 4
Stocktwits 4
MT Newswires 2
MarketBeat 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 20
Regulatory and legal 7
Deals and strategy 3
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Stock Titan Direct company coverage

EMA Panel Recommends First EU Orphan Designation for Rare Skin Disease

Vanda Pharmaceuticals announced that the European Medicines Agency (EMA) has issued a positive opinion recommending orphan drug designation for its investigational product, imsidolimab, for the treatment of generalized pustular psoriasis (GPP). This marks the first time the EMA h

Tone
Positive 72/100
Event
Regulatory and legal
Published
16 Jul 2026 20:09
Source
Stock Titan
PR Newswire Direct company coverage

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Vanda Pharmaceuticals announced that the European Medicines Agency (EMA) has issued a positive opinion recommending orphan drug designation for imsidolimab, their investigational treatment for generalized pustular psoriasis (GPP). This marks the first time a drug for GPP has rece

Tone
Positive 72/100
Event
Regulatory and legal
Published
16 Jul 2026 16:30
Source
PR Newswire
Simply Wall Street Direct company coverage

Insider Sellers Might Regret Selling Vanda Pharmaceuticals Shares at a Lower Price Than Current Market Value

Insiders of Vanda Pharmaceuticals Inc. sold US$2.8 million worth of stock over the last year at an average price of US$8.20, which is lower than the current share price but still higher than the latest price of US$5.85 after an 11% value drop. Despite the insider selling, the com

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 10:42
Source
Simply Wall Street
Sahm Direct company coverage

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

Vanda Pharmaceuticals Inc. announced that its new medication, NEREUS™ (tradipitant), which prevents motion-induced vomiting, will sponsor the No. 47 entry in the NTT IndyCar Series. This sponsorship highlights NEREUS™ as the first new prescription motion sickness treatment in the

Tone
Positive 73/100
Event
Market update
Published
16 Jul 2026 10:09
Source
Sahm
Pluang Direct company coverage

Vanda Pharma's new motion sickness drug NEREUS™ sponsors No. 47 IndyCar, marking a 47-year treatment milestone

Vanda Pharmaceuticals announced that its new FDA-approved motion sickness drug, NEREUS™ (tradipitant), will sponsor the No. 47 IndyCar, highlighting it as the first new prescription treatment for motion-induced vomiting in 47 years. This partnership underscores the drug's signifi

Tone
Positive 81/100
Event
Deals and strategy
Published
15 Jul 2026 21:45
Source
Pluang
Stock Titan Direct company coverage

47 years since the last new motion-sickness treatment, NEREUS will sponsor IndyCar

Vanda Pharmaceuticals announced that its NEREUS™ (tradipitant) medication, the first new prescription treatment for motion-induced vomiting in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series. This partnership with Rahal Letterman Lanigan Racing highlights NEREUS

Tone
Positive 67/100
Event
Deals and strategy
Published
15 Jul 2026 20:45
Source
Stock Titan
AutoRacing1.com Direct company coverage

IndyCar News: Vanda Pharmaceuticals Sponsor Schumacher for Four Races

Vanda Pharmaceuticals, a biopharmaceutical company, announced its sponsorship of Mick Schumacher's No. 47 NTT INDYCAR SERIES entry for four races in 2026. The sponsorship will feature Vanda's NEREUS™ product, an oral neurokinin-1 (NK-1) receptor antagonist for motion-induced vomi

Tone
Positive 70/100
Event
Market update
Published
15 Jul 2026 19:45
Source
AutoRacing1.com
Kavout | AI Direct company coverage

Has Vanda Pharmaceuticals Finally Found Its Game-Changer with Bysanti

Vanda Pharmaceuticals (VNDA) recently received FDA approval for Bysanti (milsaperidone) for bipolar I disorder and schizophrenia, expanding its psychiatric drug portfolio. Despite an initial sell-off, this approval, coupled with long patent protection, positions Bysanti as a pote

Tone
Positive 66/100
Event
Regulatory and legal
Published
15 Jul 2026 16:45
Source
Kavout | AI
Quantisnow Direct company coverage

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Vanda Pharmaceuticals announced that its investigational therapy for Charcot-Marie-Tooth Disease Type 2S has received Rare Pediatric Disease Designation from the FDA. This news was delivered via Quantisnow's real-time market data platform. The designation highlights the potential

Tone
Positive 70/100
Event
Regulatory and legal
Published
08 Jul 2026 10:41
Source
Quantisnow
GuruFocus Direct company coverage

Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation

Vanda Pharmaceuticals (VNDA) has received FDA Rare Pediatric Disease Designation for VCA-894A, an experimental therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S). This designation is a critical step for addressing the rare genetic disorder and could lead to a priori

Tone
Positive 70/100
Event
Market update
Published
07 Jul 2026 21:51
Source
GuruFocus
Stocktwits Direct company coverage

VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy

Vanda Pharmaceuticals (VNDA) saw its stock rise after-hours following the FDA's granting of Rare Pediatric Disease Designation for VCA-894A, its experimental treatment for Charcot-Marie-Tooth disease type 2S. This designation could make Vanda eligible for a priority review vouche

Tone
Positive 73/100
Event
Market update
Published
07 Jul 2026 20:22
Source
Stocktwits
AD HOC NEWS Direct company coverage

Vanda Pharmaceuticals updates investors on business outlook as shares trade in the U.S. market

Vanda Pharmaceuticals, a U.S.-based biopharmaceutical company, continues to develop treatments in neurology, psychiatry, and sleep medicine, with its shares trading on the American market. The company focuses on specialty prescription drugs, generating revenue from approved thera

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 17:11
Source
AD HOC NEWS
Finviz Direct company coverage

VNDA - Vanda Pharmaceuticals Inc Volatility & Greeks

This article provides a detailed overview of Vanda Pharmaceuticals Inc. (VNDA), including its latest stock performance, key financial metrics, volatility, and options Greeks. It covers market capitalization, recent earnings data, insider and institutional ownership, and various p

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 00:41
Source
Finviz
McDermott Will & Schulte Direct company coverage

McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY®

McDermott Will & Emery represented Vanda Pharmaceuticals Inc. in its acquisition of US and Canadian rights to PONVORY®, a treatment for relapsing forms of multiple sclerosis. The McDermott deal team was led by Kristian Werling with support from numerous other attorneys. This acqu

Tone
Positive 70/100
Event
Deals and strategy
Published
03 Jul 2026 21:41
Source
McDermott Will & Schulte
Insider Monkey Direct company coverage

Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)

H.C. Wainwright has reiterated a Buy rating for Vanda Pharmaceuticals (VNDA) with a $21 price target, following an update on the company's FDA approval process for HETLIOZ as a jet lag treatment. The FDA has granted Vanda a formal hearing, a rare event, to discuss the drug's appr

Tone
Positive 65/100
Event
Analyst action
Published
03 Jul 2026 13:40
Source
Insider Monkey
www.marketscreener.com Direct company coverage

Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index

Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Defensive Index. This news comes amidst other recent updates for the biopharmaceutical company, including its Q1 2026 earnings call, raising its full-year 2026 revenue guidance, and the U.S. commerc

Tone
Negative 31/100
Event
Earnings
Published
29 Jun 2026 18:11
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index

Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Value-Defensive Index. This announcement follows several recent company updates, including its Q1 2026 earnings call, raised revenue guidance, and the U.S. launch of its motion sickness drug Nereus.

Tone
Negative 30/100
Event
Earnings
Published
29 Jun 2026 07:39
Source
www.marketscreener.com
TradingView Direct company coverage

Price to book forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA

This article provides financial information for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), specifically focusing on its "Price to book forward" metric. It appears to be a financial data snippet from TradingView, indicating market closed status and offering an overview of financia

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 07:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Vanda Pharmaceuticals Inc. – FWB:VM4

This article provides financial information for Vanda Pharmaceuticals Inc. (FWB:VM4), specifically focusing on its price-to-earnings forward ratio. The content lists the company's stock exchange details, and indicates that the market was closed with no trades recorded at the time

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 06:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA

This article provides the "Price to earnings forward" value for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), indicating it's a financial metric available on TradingView. The content primarily focuses on presenting this specific data point for the company, accessible through its fin

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 05:39
Source
TradingView